AI Article Synopsis
- Many patients in the UK and Ireland do not receive bone protection medication after a hip fracture, even though intravenous zoledronate can lower refracture risk by a third.
- The use of intravenous zoledronate varies significantly among hospitals, with some providing it and others not, often due to clinical uncertainties and practical concerns.
- This paper aims to address these issues and offers expert consensus guidance to help healthcare professionals implement local protocols for administering this effective treatment before patients are discharged from the hospital.
Article Abstract
Currently in the UK and Ireland, after a hip fracture most patients do not receive bone protection medication to reduce the risk of refracture. Yet randomised controlled trial data specifically examining patients with hip fracture have shown that intravenous zoledronate reduces refracture risk by a third. Despite this evidence, use of intravenous zoledronate is highly variable following a hip fracture; many hospitals are providing this treatment, whilst most are currently not. A range of clinical uncertainties, doubts over the evidence base and practical concerns are cited as reasons. This paper discusses these concerns and provides guidance from expert consensus, aiming to assist orthogeriatricians, pharmacists and health services managers establish local protocols to deliver this highly clinically and cost-effective treatment to patients before they leave hospital, in order to reduce costly re-fractures in this frail population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542103 | PMC |
| http://dx.doi.org/10.1093/ageing/afad172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!